ITGI Medical Ltd. (TASE:ITGI) has obtained EU CE Mark for its latest version of its pericardium covered stent - the AneuGraftNx. ITGI’s share price rose 66% on the announcement to NIS 0.118, giving a market cap of NIS 13 million.
The AneuGraftNx stent is designed for specific neurological indications, including endovascular treatment of intracranial aneurysms, carotid cavernous fistuals, and intracranial dissections. ITGI will continue to collate clinical data on the new stents, which have been found to be safe and effective in previous trials, ahead of the commercial launch in a few months.
